• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Revelation Biosciences Inc. (Amendment)

    3/10/22 4:03:38 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REVB alert in real time by email
    SC 13G/A 1 karpus-sch13g_18580.htm KARPUS INVESTMENT MGT / REVELATION BIOSCIENCES - SCHEDULE 13G/A(#2)

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

      (Amendment No. 2) *

     

     

    Revelation Biosciences, Inc.

    (Name of Issuer)

       

    Common

     

    (Title of Class of Securities)

      

    716421102

     

    (CUSIP Number)

      

    February 28, 2022

     

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒   Rule 13d-1(b)

    ☐   Rule 13d-1(c)

    ☐   Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

    CUSIP No.  716421102

    13G Page 2 of 5 Pages    

    1.  

    NAME OF REPORTING PERSON(S)

     

    Karpus Investment Management

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☒

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    New York 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5.

     

    SOLE VOTING POWER

     

    0 Shares

     

      6.  

    SHARED VOTING POWER

     

    0 Shares

     

      7.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8.  

    SHARED DISPOSITIVE POWER

     

    0 Shares

     

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0 Shares

     

       
    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    0%

     

       

     12.

     

    TYPE OF REPORTING PERSON

       

    IA

     

       

     

     
     

    CUSIP No.  716421102

    13G Page 3 of 5 Pages    

     

     

    Item 1(a). Name of Issuer:

     

    Revelation Biosciences, Inc.

     

     

     

    Item 1(b). Address of Issuer's Principal Executive Offices:

     

    5 West 21st Street, New York, NY 10010

     

     

     

    Item 2(a). Name of Person Filing:

     

    This statement is being filed by Karpus Management, Inc., d/b/a Karpus Investment Management (“Karpus” or the “Reporting Person”). Karpus is a registered investment adviser under Section 203 of the Investment Advisers Act of 1940. Karpus is controlled by City of London Investment Group plc (“CLIG”), which is listed on the London Stock Exchange. However, in accordance with SEC Release No. 34-39538 (January 12, 1998), effective informational barriers have been established between Karpus and CLIG such that voting and investment power over the subject securities is exercised by Karpus independently of CLIG, and, accordingly, attribution of beneficial ownership is not required between Karpus and CLIG.

     

    The Shares to which this Schedule 13G relates are owned directly by the accounts managed by Karpus.

     

     

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    183 Sully's Trail, Pittsford, New York 14534.

     

     

     

    Item 2(c). Citizenship:

     

    The members of the Karpus Management Committee are US citizens. Karpus is a New York corporation.

     

     

     

    Item 2(d). Title of Class of Securities.

     

    Common

     

     

     

    Item 2(e). CUSIP Number.

     

    716421102

     

     

      

    Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)  ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

     

    (b)  ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     
    (c)  ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     
    (d)  ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
    (e)  ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
    (f)  ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
    (g)  ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
    (h)  ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)  ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ☐  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
    (k)  ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     
     

    CUSIP No.  716421102

    13G Page 4 of 5 Pages    

     

     

    Item 4. Ownership:

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a)       Amount beneficially owned:   0

    (b)       Percent of Class:    0%

    (c)       Number of shares as to which such person has:

    (i)     Sole power to vote or direct the vote:    0

    (ii)    Shared power to vote or direct the vote:     0

    (iii)   Sole power to dispose or to direct the disposition of:    0

    (iv)   Shared power to dispose or to direct the disposition of:     0

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date herof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:   ☒

     

      

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security being Reported on by the Parent Holding Company.

     

    Not applicable.

     

     

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

     

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

    CUSIP No.  716421102

    13G Page 5 of 5 Pages    

     

     

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated:                   March 10, 2022

     

     
    KARPUS MANAGEMENT, INC.

     
           
    By:
    /s/ Jodi L.Hedberg  
        Name:  Jodi L. Hedberg  
        Title:    Chief Compliance Officer  
           

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $REVB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $REVB

    DatePrice TargetRatingAnalyst
    2/17/2022$12.00Buy
    Roth Capital
    More analyst ratings

    $REVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received gross proceeds of $4 million from public offering in May 2025 "The Revelation team continues to strategically maximize its financial resources to achieve our stated objectives and advance the Gemini program," said James Rolke, Chief Executive Officer of Revelation. "We look forward to announcing data fr

    8/8/25 6:30:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

    Revelation Biosciences, Inc. (NASDAQ:REVB) the "Company" or "Revelation") a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today congratulates its former chairman and shareholder, George Tidmarsh, MD, PhD, who has been selected to head the FDA Center for Drug Evaluation and Research. "George was the chairman of the board of our company, Revelation Biosciences, Inc., as well as one of the founders," said James Rolke, President and CEO, Revelation. "We wish to thank George for his guidance and support during his tenure on the Revelation board as well as for the time we worked together at La Jolla Pharmaceutical Company." Dr. Tidmarsh trained a

    7/24/25 9:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

    – Sample analysis and data collection ongoing – – Data expected during Q3 2025 – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). As planned, a total of 5 cohorts were enrolled at 3 clinics in the United States. Several study data sets are expected during Q3 2025: these will include safety parameters, changes in hematologic pa

    7/16/25 9:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Revelation Biosciences with a new price target

    Roth Capital initiated coverage of Revelation Biosciences with a rating of Buy and set a new price target of $12.00

    2/17/22 8:17:25 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chawla Lakhmir S was granted 181 shares (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    2/13/25 6:14:40 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carver Jennifer was granted 181 shares, increasing direct ownership by 3,017% to 187 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    2/13/25 6:12:17 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Roper Jess was granted 181 shares, increasing direct ownership by 9,050% to 183 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    2/13/25 6:09:20 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Financials

    Live finance-specific insights

    View All

    Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients "While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe bu

    5/8/25 4:15:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FDA Acceptance of Gemini IND Received net proceeds of $3.7 million from the exercise of warrants in December 2024 "We made significant progress at the end of last year and hope to continue that pace in 2025," said James

    3/6/25 4:15:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Received net proceeds of $3.8 million from the exercise of warrants in August 2024 Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers "The Revelation team continues to make significan

    11/8/24 4:15:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Leadership Updates

    Live Leadership Updates

    View All

    Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

    5/23/25 4:05:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

    – A vote for Proposal 2 saves the Company over $200,000 per year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All proposals in the proxy are important and the Board of Directors has suggested a vote for all proposals. Please vote by calling Advantage Pr

    1/13/25 6:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

    Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company's Board of Directors (Board). "We are excited to welcome Dr. Chawla as an independent director to our Board," said James Rolke, Chief Executive Officer of Revelation. "Dr. Chawla brings decades of expertise and leadership in key areas such as nephrology, critical care medicine, drug development and strategic implementation. I am confident that he will provide valuable perspectives as we continue to execute our str

    10/2/23 9:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Revelation Biosciences Inc. (Amendment)

    SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

    2/13/24 8:12:05 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Revelation Biosciences Inc.

    SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

    1/3/24 8:36:37 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Revelation Biosciences Inc.

    SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

    2/21/23 4:49:56 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    SEC Filings

    View All

    Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    8/8/25 8:10:23 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    7/9/25 4:17:31 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    6/25/25 4:26:46 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care